AACR 2023 | Petosemtamab has promising activity in advanced HNSCC

Ezra Cohen, MD, FRCPSC, FASCO, Moores Cancer Center at UC San Diego Health, San Diego, CA, discusses the clinical activity of petosemtamab, a bispecific antibody targeting EGFR and LGR5, in patients with head and neck squamous carcinoma (HSNCC). Patients who are refractory to anti PD-(L)1 blockade and platinum therapy represent an unmet need, and encouraging clinical activity was reported in this patient population. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.